Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
A phase 3, multicenter, randomized, double-blind, placebo-controlled study of rilotumumab in combination with cisplatin and capecitabine (CX) as first-line therapy for Asian patients (pts) with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma:the RILOMET-2 trial [abstract]
Extended exposure to temperatures above 77 degrees Fahrenheit accelerates degradation
In all these models, the iodine transporter, thyroid follicular cells, and TSH receptors are the main targets
Available from Last accessed Nov
This unique receptor engagement is actively investigated in research environments to observe metabolic regulation, cellular energy expenditure, and lipid metabolism pathways
US$ 24.84
US$ 29.84
US$ 28.89
US$ 24.76
US$ 20.27
